GLP-1 weight-loss medicines work by mimicking the natural hormones your gut releases after eating — the ones that tell your brain "you're full". They don't burn fat, speed up metabolism or melt anything away. They change the signals that drive hunger, so eating less stops being a daily battle of willpower and starts feeling like your default.
The hormone your body already makes
When you eat, your intestine releases glucagon-like peptide-1 (GLP-1). This hormone does several useful things at once: it tells your brain's appetite centres you've had enough, slows the rate food leaves your stomach so fullness lasts longer, and prompts your pancreas to release insulin when blood sugar rises. Natural GLP-1 is broken down within minutes — which is where the medicines come in.
What the medicines change
Semaglutide (the active ingredient in Wegovy) is a modified, long-lasting version of GLP-1 that stays active for about a week per dose instead of minutes. Tirzepatide (Mounjaro) goes a step further: it activates the GLP-1 receptor and a second gut-hormone receptor called GIP, which appears to amplify the effect on appetite and metabolism.
The practical result, reported consistently by patients and measured in trials:
- Reduced hunger — you think about food less between meals
- Earlier fullness — smaller portions genuinely satisfy
- Quieter "food noise" — the constant background pull toward snacking fades for many people
- Steadier blood sugar — fewer energy crashes that trigger cravings
Why the dose increases gradually
Every GLP-1 medicine starts at a low dose and steps up over weeks to months. This isn't marketing — it's how the body adapts. Slowed stomach emptying is central to how these medicines work, and it's also what causes the common early side effects (nausea, bloating, constipation). Starting low and titrating slowly lets your digestive system adjust, which is why most side effects fade with time and reappear briefly after each increase.
What the trials show
In placebo-controlled trials, semaglutide 2.4 mg produced around 15% average body-weight loss over 68 weeks (STEP 1), and tirzepatide up to around 21% over 72 weeks at the highest dose (SURMOUNT-1) — both alongside diet and activity support. These are averages: some people lose considerably more, some less, and response in the first months is a reasonable predictor of longer-term results.
Why "alongside lifestyle changes" isn't small print
The medicine controls appetite; it doesn't choose what's on your plate. Trial participants received diet and activity support because the combination is what produces those results. The medicine creates a window where healthier habits are dramatically easier to build — protein-first eating, regular movement, better sleep. Those habits are also what protect you if you ever reduce or stop treatment, because appetite returns when the medicine is withdrawn.
The bottom line
GLP-1 medicines treat the biology of appetite rather than blaming willpower — which is why they work where diets alone often haven't. They're prescription-only for good reason: a clinical assessment determines whether they're suitable and safe for you, and prescriber oversight makes titration safe and effective.
Frequently asked questions
Do GLP-1 injections burn fat?
No — they reduce appetite and slow stomach emptying, so you eat less. The weight loss comes from the resulting calorie deficit, which is why protein and exercise matter for keeping the loss to fat rather than muscle.
How quickly do GLP-1 medicines start working?
Appetite effects usually appear within the first days to weeks, but doses start low, so meaningful weight change typically builds over the first two to three months as the dose titrates up.
What is "food noise"?
The persistent background preoccupation with food — thinking about the next meal, snacking impulses, cravings. Many patients report GLP-1 medicines quieten it markedly, which is often described as the biggest day-to-day change.
Will I regain weight if I stop?
Appetite generally returns once the medicine is stopped, and trials show partial regain is common without continued treatment or strong habits. This is why building lasting eating and activity habits during treatment matters so much.
References
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216.
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–756.
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 extension). Diabetes Obes Metab. 2022.